Menu

Alternate Dosing Strategies for Beta-hydroxy-beta-methylbutyrate (HMB) Supplementation: Effect on Plasma HMB Responses

Status

Completed

Conditions

Focus of the Study is to Examine Plasma HMB Levels After Oral HMB Supplementation

Treatments

Dietary Supplement: HMB free acid
Dietary Supplement: CaHMB in water
Dietary Supplement: HMB free acid gelcap
Dietary Supplement: CaHMB capsule
Dietary Supplement: HMB free acid mixed in water

Study type

Interventional

Funder types

Industry

Identifiers

NCT01914952
MTI2013-CS02

Details and patient eligibility

About

The purpose of this study is to examine the rise in plasma Beta-hydroxy-beta-methylbutyrate (HMB) after the dietary supplement has been administered in different forms. Prior studies have indicated that form of administration affects bioavailability of the HMB supplement. Therefore the current study will examine the bioavailability of a single dose of HMB given as:

  • 1.0g CaHMB in gelatin capsule
  • 0.8 g HMB free acid in a gelcap
  • 0.8 g HMB free acid in water
  • 1.0 g CaHMB in water
  • 0.8 g HMB free acid

The randomized study will be a crossover design and each study subject will undergo the experimental protocol for each of the supplementation forms. Because of the different administration forms, the study will be an open label study. Briefly, the fasted participants will report to the laboratory in the morning. After an initial blood sample is taken, the dose of HMB will be administered. Blood will then be samples at 2, 5, 10, 15, 25, 35, 45, 60, 90, 120, 180, 360, 720, and 1440 min post administration. A 24 h complete urine collection will also be performed. Participants will be given a light sack lunch 4 h after administration of the dosage and will remain at the laboratory through the 360 min sampling. Participants will then be allowed to leave the laboratory and return for the 720 min sampling after which the participants can eat an normal evening meal. Participants will return to the laboratory fasted the next morning for the final sample. A minimum 48 h washout period will be required before the next dosage form is administered and the process repeated.

Enrollment

11 patients

Sex

All

Ages

18 to 30 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Must not be taking amino acid, protein, or HMB supplements; Must not be pregnant; Must not be breastfeeding

Exclusion criteria

  • Currently taking amino acid, protein, or HMB supplements; Currently pregnant; Currently breastfeeding

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

11 participants in 5 patient groups

CaHMB Capsule
Active Comparator group
Treatment:
Dietary Supplement: CaHMB capsule
HMB free acid gelcap
Active Comparator group
Treatment:
Dietary Supplement: HMB free acid gelcap
HMB free acid in water
Active Comparator group
Treatment:
Dietary Supplement: HMB free acid mixed in water
CaHMB powder in water
Active Comparator group
Treatment:
Dietary Supplement: CaHMB in water
HMB free acid (oral not in gelcap or water)
Active Comparator group
Treatment:
Dietary Supplement: HMB free acid

Trial contacts and locations

1

There are currently no registered sites for this trial.

Timeline

Last updated: Sep 16, 2014

Start date

May 01, 2013 • 12 years ago

End date

May 01, 2014 • 11 years ago

Today

May 07, 2025

Sponsor of this trial

Data sourced from clinicaltrials.gov